ProShare Advisors
FLGT icon

ProShare Advisors’s Fulgent Genetics FLGT Stock Holding History

ProShare Advisors’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,589
Closed -$286K – 1914
2022
Q1 		$286K Sell
4,589
-580
-11% -$38.2K ﹤0.01% 1658
2021
Q4 		$520K Buy
5,169
+2,025
+64% +$178K ﹤0.01% 1406
2021
Q3 		$283K Sell
3,144
-2,601
-45% -$236K ﹤0.01% 1592
2021
Q2 		$530K Buy
5,745
+1,603
+39% +$128K ﹤0.01% 1497
2021
Q1 		$400K Buy
+4,142
New +$428K ﹤0.01% 1601

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ProShare Advisors's FLGT Position: Q2 2022 in Review

ProShare Advisors sold out of Fulgent Genetics (FLGT) in Q2 2022, closing a stake of 4,589 shares — an estimated $286K sold.

ProShare Advisors first reported a position in FLGT in Q1 2021 and held it in 5 quarters. The position peaked at $530K in Q2 2021. 262 funds tracked by Wall St. Rank hold FLGT as of Q2 2022.

  • ProShare Advisors reported no remaining Fulgent Genetics position as of Q2 2022 after selling out during the quarter.
  • ProShare Advisors sold 4,589 Fulgent Genetics shares in Q2 2022, an estimated $286K.
  • ProShare Advisors first reported a position in Fulgent Genetics in Q1 2021 and held it in 5 quarters.
  • ProShare Advisors's Fulgent Genetics position peaked at $530K in Q2 2021.
  • 262 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.